656-P: Antifibrotic Potential of a Novel Long-Acting Glucagon/GIP/GLP-1 Triple Agonist (HM15211) in Preclinical Models of Fibrosis

Fibrosis due to nonalcoholic steatohepatitis (NASH) remains a major cause of liver-related mortality. Since complex biological pathways are involved in fibrosis progression, multi-disciplinary therapeutic approaches should be required to effectively deliver treatment effects on fibrosis. For this pu...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Diabetes (New York, N.Y.) N.Y.), 2021-06, Vol.70 (Supplement_1)
Hauptverfasser:	KIM, JUNG KUK, LEE, JONG SUK, LEE, SEON MYEONG, KWON, HYUNJOO, CHOI, JAEHYUK, PARK, EUNJIN, BAE, SUNGMIN, KIM, DAEJIN, KIM, YOUNG HOON, CHOI, IN YOUNG
Format:	Artikel
Sprache:	eng
Schlagworte:	Agonists Animal models Choline Collagen Diabetes Fibrosis Glucagon High fat diet Hyaluronic acid Hydroxyproline Liver Thioacetamide Tissue inhibitor of metalloproteinase 1
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!